Anavex Lf SC Cmn (AVXL) 3.11 $AVXL Anavex Life
Post# of 273254
Posted On: 09/25/2016 9:17:34 PM
Anavex Lf SC Cmn (AVXL) 3.11 $AVXL
Anavex Life Sciences' Drug Shows Efficacy to Support Potential Disease Modification in Parkinson's Disease
GlobeNewswire - Thu Sep 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL) today presented preclinical data demonstrating that ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson's disease. Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints.
AVXL: 3.11 (-0.17)
Anavex to Present at Ladenburg Thalmann 2016 Healthcare Conference
GlobeNewswire - Tue Sep 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference.
AVXL: 3.11 (-0.17)
Anavex to Participate in Mizuho Therapeutics Conference
GlobeNewswire - Wed Sep 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in Mizuho Therapeutics Conference on Wednesday, September 21, 2016. The conference will be held at the Langham Hotel in Boston, Massachusetts.
AVXL: 3.11 (-0.17)
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.11 (-0.17), STEM: 1.43 (+0.03), PETX: 9.28 (-0.13), THLD: 1.17 (-0.05)
Anavex Reports Fiscal Third Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:15PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and nine months ended June 30, 2016.
AVXL: 3.11 (-0.17)
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
GlobeNewswire - Fri Jul 29, 8:20AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 3.11 (-0.17)
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.11 (-0.17)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.11 (-0.17), ANIP: 66.64 (-0.17), RTRX: 22.57 (-0.70), ACOR: 27.28 (+0.06)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms.
AVXL: 3.11 (-0.17)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 11.41 (-0.21), PACB: 9.13 (-0.17), AVXL: 3.11 (-0.17), PPHM: 0.41 (-0.01)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.11 (-0.17)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
AVXL: 3.11 (-0.17)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
AVXL: 3.11 (-0.17)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats.
AVXL: 3.11 (-0.17)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 3.11 (-0.17)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 3.11 (-0.17)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.11 (-0.17)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.39 (-0.06), TPUB: 13.96 (+0.17), AVXL: 3.11 (-0.17), NEOT: 1.22 (-0.03)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company" (NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline.
AVXL: 3.11 (-0.17)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 3.11 (-0.17)
Anavex Life Sciences' Drug Shows Efficacy to Support Potential Disease Modification in Parkinson's Disease
GlobeNewswire - Thu Sep 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL) today presented preclinical data demonstrating that ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson's disease. Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints. AVXL: 3.11 (-0.17)
Anavex to Present at Ladenburg Thalmann 2016 Healthcare Conference
GlobeNewswire - Tue Sep 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference. AVXL: 3.11 (-0.17)
Anavex to Participate in Mizuho Therapeutics Conference
GlobeNewswire - Wed Sep 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in Mizuho Therapeutics Conference on Wednesday, September 21, 2016. The conference will be held at the Langham Hotel in Boston, Massachusetts. AVXL: 3.11 (-0.17)
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.11 (-0.17), STEM: 1.43 (+0.03), PETX: 9.28 (-0.13), THLD: 1.17 (-0.05)
Anavex Reports Fiscal Third Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:15PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and nine months ended June 30, 2016. AVXL: 3.11 (-0.17)
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
GlobeNewswire - Fri Jul 29, 8:20AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73. AVXL: 3.11 (-0.17)
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.11 (-0.17)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.11 (-0.17), ANIP: 66.64 (-0.17), RTRX: 22.57 (-0.70), ACOR: 27.28 (+0.06)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms. AVXL: 3.11 (-0.17)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 11.41 (-0.21), PACB: 9.13 (-0.17), AVXL: 3.11 (-0.17), PPHM: 0.41 (-0.01)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.11 (-0.17)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT. AVXL: 3.11 (-0.17)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome. AVXL: 3.11 (-0.17)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats. AVXL: 3.11 (-0.17)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 3.11 (-0.17)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016. AVXL: 3.11 (-0.17)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.11 (-0.17)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.39 (-0.06), TPUB: 13.96 (+0.17), AVXL: 3.11 (-0.17), NEOT: 1.22 (-0.03)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company"
(NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline. AVXL: 3.11 (-0.17)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 3.11 (-0.17)
(0)
(0)Scroll down for more posts ▼